Area of research
Rheumatology · Pharmacology
Research interest
Research interests include Rheumatoid Arthritis Research and Therapies, Inflammatory mediators and NSAID effects, Osteoarthritis Treatment and Mechanisms, and Systemic Lupus Erythematosus Research.
Impact of the COVID-19 Pandemic on People Living with Rheumatoid Arthritis: Experiences and Preferences in Accessing Healthcare Across Five Countries.
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey
Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys
Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study
A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
Sex differences in gout characteristics: tailoring care for women and men
Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of <scp>US</scp> Patients With Rheumatoid Arthritis
Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors
Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial
SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012
Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis.
PubMed 2012cited by 416position: first
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement